Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
A Next-generation Sequencing Analysis to Investigate the Clinical Impact of Concomitant Genetic Alterations in the Patients With Advanced EGFR-mutated Lung Adenocarcinoma: A Multicenter Study.
Sponsor: Foundation Medicine
Listed as NCT04122833, this observational or N/A phase trial focuses on Adenocarcinoma of Lung and EGFR Activating Mutation and remains ongoing. Sponsored by Foundation Medicine, it has been updated 9 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Feb 2025 — Sep 2025 [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Sep 2022 — Jun 2024 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Jan 2022 — Sep 2022 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting
-
Nov 2019 — Jan 2021 [monthly]
Recruiting
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Foundation Medicine
- Konkuk University Medical Center
- Roche Diagnostics GmbH
For direct contact, visit the study record on ClinicalTrials.gov .